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breathingIn Allergology International (AI) Vol. 64 No. 2, we offer a set of re-
view articles entitled “Regulation of upper airway inﬂammation fa-
cilitates comfortable breathing,” as well as original articles and
letters to the editor. We believe that this review series will provide
you with the latest concepts in chronic rhinosinusitis (CRS) and
allergic rhinitis (AR).
CRS and AR are the most widespread nasal diseases. CRS was
dominant before 1980; thick, yellow, or greenish discharge drained
from the noses of many children or was swallowed. For many adult
CRS patients, Caldwell-Luc operations, which completely resect
nasal mucosa in sinuses, were performed over a period of nearly
100 years, from 1893 through the mid-1980s. Then in 1986, Ken-
nedy and Stammberger established a functional type of endoscopic
sinus surgery to preserve sinusmucosa. Their approach has evolved
into endoscopic sinus surgery (ESS), which has now become the
standard treatment for CRS with nasal polyps (CRSwNP). The
outcome of ESS is superior to that of the Caldwell-Luc operation.
Furthermore, a long-term low-dose macrolide treatment has been
developed for CRS patients. In East Asia, the combination of ESS
and long-term, low-dose macrolide treatment is very effective for
CRS patients because neutrophil inﬁltration is typically dominant
in the nasal mucosa of East Asian CRS patients and neutrophil-
dominant CRS responds well to macrolide treatment.
In Western countries, CRS is usually classiﬁed into CRS without
nasal polyps (CRSsNP) and CRSwNP. It is generally accepted that
CRSwNP is characterized by Th2-skewed eosinophilic inﬂamma-
tion, whereas CRSsNP is found in a Th1-predominant milieu. Eighty
percent of the CRSwNP patients in Western countries showed
eosinophilia in the lamina propria as well as in the epithelium of
NP.1 In this issue, Kato describes the different characteristics of
CRSwNP inWestern and in Asian countries.2 He also focuses on im-
mune cells and cytokines that control the initiation and ampliﬁca-
tion of CRS inﬂammation, demonstrating the involvement of B cell
lineages, mast cells, dendritic cells, and ILC2 in the pathogenesis of
CRSwNP.
Worldwide, the prevalence of AR has recently increased,
whereas the prevalence of CRS has decreased. The “hygiene hy-
pothesis” has been advocated to explain this phenomenon. Sea-
sonal AR caused by Japanese cedar pollen (SAR-JCP), Japanese
cedar pollinosis (JCP), is now the most common disease in Japan
and has been called a “national afﬂiction.”3 More than one-third
of all Japanese people suffer from JCP. The “one airway, one disease”Peer review under responsibility of Japanese Society of Allergology.
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AR and atopic asthma. Furthermore, the association between CRS
and asthma as well as AR has been recently pointed out, which is
now called the second “one airway, one disease” theory, Okano
et al. describe in their review article the association of eosinophilic
inﬂammation between the upper and lower airways.4 They focus
on the epidemiology of AR and CRS, the effects of upper airway dis-
eases on lower airway inﬂammation, and the intervention effects
for upper airway diseases on the natural courses of bronchial
asthma. Allergen immunotherapy, a curative treatment for AR,
modiﬁes the natural course of asthma. The pharmacotherapies for
AR and CRS patients decrease the symptoms of asthma. Turbinate
surgery for AR improves not only nasal symptoms, but also asthma
control. Moreover, sinus surgeries for CRS patients with bronchial
asthma improve their lower airway functions. They emphasize
the importance of treatments for AR and CRS to improve the symp-
toms and the pulmonary functions of asthma patients, letting them
breathe comfortably.
Among the contributors to this issue, Matsusaka et al. have
analyzed serum periostin levels in 190 asthma patients and charac-
terized “high-periostin” phenotypes.5 Bronchial asthma is now
considered a heterogeneous disease consisting of subgroups with
different pathological backgrounds. To design optimal therapeutic
approaches, it is of great importance to discriminate among asthma
subgroups. Matsusaka and her colleagues identiﬁed as the “high-
periostin” phenotype those patients manifesting eosinophilic-
dominant, late-onset disease complicated by obstructive pulmo-
nary dysfunction and nasal disorders. It has already been demon-
strated that high serum periostin is associated with good
responsiveness to type 2 antagonists such as anti-IL-13 antibodies
and poor responsiveness to inhaled corticosteroids.6,7 Their results
may provide us with a therapeutic strategy for this speciﬁc pheno-
type of bronchial asthma.
Murakami et al. report the results of a prospective, randomized,
short-term oral immunotherapy (OIT) for JCP.8 Pharmacological
treatments with antihistamines and corticosteroid nasal sprays
offer temporary relief but are not curative. Thus far, subcutaneous
and sublingual immunotherapies (SCIT and SLIT) are available as
curative treatments for JCP. However, these treatments must be
taken for long periods, usually a few years. OIT has an advantage
in inducing immunotolerance in a short time because patients
can take large amounts of antigen. They used galactomannan-
conjugated Cry j 1 in this study to decrease the risk of adverse ef-
fects and to avoid digestion and accelerate the uptake of antigensevier B.V. All rights reserved.
Editorial / Allergology International 64 (2015) 119e120120in the gut. Their results indicate that administration starting one
month before the peak pollen season is effective for improving
symptoms and decreasing medication. Short-term OIT using the
Cry j 1-galactomannan conjugate shows promise as a future
replacement for SLIT or SCIT for JCP.
Takai et al. reported on the work of a Japanese Society of Aller-
gology (JSA) task force regarding standardization of house dust
mite (HDM) allergen vaccines.9 Standardizing allergen vaccines/ex-
tracts is necessary for diagnosis and therapy. Whereas JCP allergen
vaccines have been standardized in Japan since the 1990s, this had
not yet been done for HDM allergen vaccines. This task force
selected the JSA reference HDM extract and determined its in vivo
allergic potency by intradermal testing. They showed that major
allergen contents can be used as a surrogate in vitro assays because
in vitro IgE binding potency is correlated with group 1 allergen (Der
1) content, group 2 allergen content, or their combined amounts.
Based on this ﬁnding, they determined that 38.5 mg/ml Der 1 con-
tent corresponds to 100,000 JAU/ml of the in vivo allergenic po-
tency and that 22.2e66.7 mg/ml of Der 1 can be labeled as
100,000 JAU/ml HDM allergen extract.
We offer our appreciation to all the authors for their contribu-
tions to the present issue of Allergology International.
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